胰腺癌的化学治疗及生物靶向治疗相关研究进展  

Research Progress of Chemotherapy and Targeted Biotherapy of Pancreatic Cancer

作　　者：陈娟[1] 陈锦云[1] 

机构地区：[1]重庆医科大学生物医学工程学院,重庆400016

出　　处：《医学综述》2014年第13期2347-2349,共3页Medical Recapitulate

基　　金：973国家重点基础研究发展计划(2012CB722402)

摘　　要：胰腺癌恶性程度极高,化学治疗(化疗)是其综合治疗中非常重要的一种方式。以吉西他滨为基础联合其他药物化疗基本上未能延长患者的生存期。在靶向治疗中,只有表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼联合吉西他滨治疗表现出活性。对于一般情况好的患者,氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂化疗方案显著优于吉西他滨。以吉西他滨、氟尿嘧啶、顺铂为基础的多药综合化疗对于胰腺癌也显示出一定的活性。在一线治疗失败后,一般情况好的患者接受二线治疗可以提高生存获益。Pancreatic cancer is one of the most malignant gastrointestinal cancers, and chemotherapy is one of the comprehensive treatments for pancreatic cancer. Gemcitabine-based combinations with other chemotherapeutics have failed to provide a substantial prolongation of survival. Among targeted therapies, only the EGFR tyrosine kinase inhibitor erlotinib has shown activity combining gemcitabine. FOLFIRINOX-regimen was shown to be superior to gemcitabine for good-performance patients. For pancreatic cancer, gemcitabine-fluoropyrimidines-platin analogs-based combination chemotherapy has shown a certain activity. After failure of first-line therapy, some patients with good-performance can benefit from second-line chemotherapy.

关 键 词：胰腺癌 化学治疗 生物靶向治疗 

分 类 号：R735.9[医药卫生—肿瘤]